Rilotumumab
Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors. Rilotumumab was in development by Amgen, Inc. until in November 2014, when Amgen announced it had halted all clinical trials of the compound in advanced gastric cancer (including two Phase III studies) after one of the trials found an increase in the number of deaths in those who were taking rilotumumab and chemotherapy when compared to those who were only administered chemotherapy.
Link from a Wikipage to another Wikipage
primaryTopic
Rilotumumab
Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors. Rilotumumab was in development by Amgen, Inc. until in November 2014, when Amgen announced it had halted all clinical trials of the compound in advanced gastric cancer (including two Phase III studies) after one of the trials found an increase in the number of deaths in those who were taking rilotumumab and chemotherapy when compared to those who were only administered chemotherapy.
has abstract
Rilotumumab (previously AMG102 ...... nly administered chemotherapy.
@en
CAS number
872514-65-3
FDA UNII code
51WEW898IJ
KEGG
Wikipage page ID
33,024,297
page length (characters) of wiki page
Wikipage revision ID
993,491,801
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
none
@en
KEGG
D09659
@en
mab type
mab
@en
source
u
@en
target
type
mab
@en
Verifiedfields
changed
@en
verifiedrevid
464,382,516
Watchedfields
changed
@en
wikiPageUsesTemplate
subject
hypernym
comment
Rilotumumab (previously AMG102 ...... nly administered chemotherapy.
@en
label
Rilotumumab
@en